Safety Profile of Feminizing Hormone Therapy in Biological Males
Feminizing hormone therapy using modern estradiol formulations (oral or transdermal) is generally safe with appropriate monitoring, though it carries a slightly increased risk of venous thromboembolism (VTE), particularly in older patients and those with additional risk factors. 1
Primary Safety Concerns
Venous Thromboembolism (VTE) - The Most Serious Risk
The most clinically significant adverse effect is VTE, but the absolute risk remains relatively low with modern regimens:
- Ethinyl estradiol (EE) is no longer recommended due to high VTE incidence (5.5-6%) when used at historical doses of 100 µg 1
- Modern oral estradiol (17β-estradiol, estradiol valerate) and conjugated equine estrogens show much lower VTE rates
- In a study of 676 transgender women on conjugated equine estrogen, only one case of VTE occurred over 1.9 years 1
- Transdermal estradiol showed no VTE cases in a 5-year study of 162 patients 1
Critical risk modifiers for VTE:
- Age >40 years - significantly increases risk 1
- Smoking - compounds thrombotic risk 1
- High BMI - associated with increased VTE 1
- Duration of therapy - risk increases after 2+ years (adjusted HR 5.1 vs cisgender men) 1
- Inherited thrombophilia - further elevates risk but absolute numbers remain manageable 1
Cardiovascular Effects
- Two- to fourfold increased cardiovascular mortality risk reported in some studies 2
- Lipid profile changes occur but typically align toward female reference ranges 3
- Route matters: Transdermal estrogen demonstrates superior cardiovascular safety profile compared to oral formulations in high-risk individuals 1
Other Documented Side Effects
Common but manageable:
- Breast development (desired effect, typically plateaus after 2-3 years) 2
- Body composition changes: 3-5.5% reduction in lean body mass, increased body fat 2
- Decreased muscle volume (4-5% reduction in quadriceps cross-sectional area) 2
- Hemoglobin reduction 2
Rare but serious:
- Meningiomas (particularly with cyproterone acetate as antiandrogen) 4
- Macroprolactinoma 5
- Breast cancer (theoretical increased risk, not definitively established) 6
- Cholelithiasis 5
- Hypertriglyceridemia 5
Hepatic effects:
- Transient liver enzyme elevations occur in 2.44-4.23% of patients 3
- Most cases resolve without intervention 3
Optimal Prescribing Strategy to Minimize Risk
Estrogen Selection and Dosing
Preferred formulations:
- Oral 17β-estradiol: 2-6 mg/day 1
- Transdermal estradiol: 0.025-0.2 mg/day 1
- Oral estradiol valerate: 2-4 mg/day 1
- Injectable estradiol valerate: 3-4 mg weekly achieves physiologic levels in 76-78% of patients 7
Avoid:
- Ethinyl estradiol in any dose 1
Route Selection Based on Risk Profile
Use transdermal estrogen preferentially in patients with:
- Age ≥40 years 1
- Previous VTE 1
- Obesity 1
- Smoking history 1
- Inherited thrombophilia 1
- Proinflammatory conditions 1
The evidence from over 80,000 cisgender women shows no increased VTE risk with transdermal preparations, even in high-risk populations 1. While head-to-head studies in transgender populations are lacking, extrapolation from HRT data strongly supports this approach.
Antiandrogen Considerations
- Spironolactone: No known VTE risk increase 1
- Cyproterone acetate: Associated with meningioma risk and potentially higher VTE risk when combined with estrogen 1, 4
- GnRH agonists: VTE risk not well-characterized 1
Monitoring Requirements
Baseline assessment must identify:
- Personal or family history of VTE
- Thrombophilia screening if indicated by history
- Cardiovascular risk factors
- Baseline liver function
- Lipid panel
- Hemoglobin/hematocrit
Ongoing surveillance:
- Liver enzymes periodically (elevations typically transient) 3
- Lipid monitoring
- Estradiol levels to confirm therapeutic range (100-300 pg/mL) 8
- Testosterone suppression (<50 ng/dL achieved in 83.6-90% with appropriate dosing) 7
Critical Clinical Pitfalls
Do not use ethinyl estradiol - this is the single most important safety measure 1
Do not ignore age as a risk factor - VTE risk substantially increases after age 40, warranting transdermal route consideration 1
Do not assume oral and transdermal routes are equivalent - while evidence is conflicting in transgender populations, transdermal has proven safety advantages in high-risk cisgender women that should inform practice 1
Do not overlook duration of therapy - VTE risk increases beyond 2 years, requiring ongoing risk assessment 1
Do not dismiss smoking cessation counseling - smoking compounds VTE risk significantly 1
Quality of Life Considerations
Despite these risks, hormone therapy demonstrates substantial quality-of-life benefits and reduction in gender dysphoria 5. A 2020 study of 388 individuals showed that guideline-based therapy is both efficient and safe, with VTE occurring in only 1.9% of transgender women 3. The risks must be weighed against the significant psychological benefits, and patients should be empowered to make informed decisions with multidisciplinary support 1.
The evidence consistently shows that when modern estradiol formulations are used (avoiding ethinyl estradiol), with appropriate patient selection and route optimization based on individual risk factors, feminizing hormone therapy has an acceptable safety profile for most patients.